Hong Kong Drug Licence Applications and Acquisitions · RGYS|Global Licensing and Compliance Service Provider
Hong Kong pharmaceutical compliance · applications / acquisitions / ongoing maintenance Independent Third-Party Service Provider
HONG KONG DRUG LICENSING

Our licensed company’s registered name has changed. Do we need to notify the Drug Office?

A complete explanation of the regulatory basis, Drew Tang’s recommendations and risk alerts. The original material dates from 2025; read it alongside the latest official requirements.

Original guide, 2025 edition: These FAQs are provided for topic-based reference and have not all been individually checked against current rules. Please confirm fees, personnel, renewal, changes and product requirements against the professional in-depth guide for the relevant licence type and the official requirements in force at the time.

Drug Office, Department of Health Chinese Medicines Board

Q413 · Category I: Renewals, changes and penalties for non-compliance (Q401–Q450)
Yes, you must notify the authority. After your company has registered its name change with the Companies Registry in Hong Kong, you should notify the Drug Office, Department of Health (or the Chinese Medicine Council, if applicable) in writing as soon as possible. You will need to provide a copy of the “Certificate of Change of Name” issued by the Companies Registry, together with the updated Business Registration Certificate. The regulatory authority needs to ensure that the legal name of the licensed entity in its records exactly matches the official records. This is essential for the validity of the licence and future renewal applications.

📘 Regulatory basis

Although this is an administrative change, licence holders are obliged to ensure that all information submitted to the regulator is up to date and accurate; this is one of the licence conditions.

📗 Drew Tang's recommendations

This step is simple but easy to forget. We recommend that any change to statutory particulars, such as the company name, address or directors, be included in the company’s standard change management process, with a designated person notifying all relevant regulatory authorities as soon as possible.

📕 Risk notice

Failure to update the company name promptly may result in regulatory correspondence not being delivered or raise questions during renewal review because the information does not match, causing unnecessary delays.

Back to Category I: Renewals, Changes and Penalties for Breaches (Q401-Q450) Search more questions

YOUR NEXT STEP

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang

Business Manager Tang Shangyong (Drew Tang) will review your products, operating model, licence type and preparation requirements with you one-to-one. The precise service scope is confirmed in writing; pharmaceutical duties are carried out by legally qualified personnel, and approvals are determined by the competent authorities.

Book a Project Assessment ↗